After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
At best, the stock should be priced at around $18, or 12% lower.
Cramer is faithful to pet care drug maker Zoetis and he prefers Danaher over its split-off sibling Fortive.
Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.
When the going gets tough, investors should snuggle up to the stable pet industry.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.